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Abstract 
The relationship between urinary incontinence and chronic obstructive pulmonary disease 
(COPD) among Japanese women is reviewed. The prevalence of COPD is increasing because 
of the aging population and the high rate of cigarette consumption. The prevalence of COPD 
in Japan was 16.4% for males and 5% for females aged 40 years and above in 2000. COPD is 
a progressive disease, which can have periods of relative stability but readily regresses. Its 
characteristic symptoms include cough, sputum production, dysponea and frequently urinary 
incontinence. The persistent cough of COPD increases intra-abdominal pressure and results in 
increased rates of urinary incontinence especially for female patients. The prevalence of 
urinary incontinence among Japanese women with chronic lung disease varied between 
30.4% and 68%, which was comparatively higher than those of the general population (25-
56.9%) and outpatient clients attending gynaecology clinics (27-31%). However, there is no 
published report specifically on the prevalence of urinary incontinence for Japanese women 
with COPD. As COPD is one of the causes of urinary incontinence, the obvious prevention 
strategy is tobacco control and early detection using screening test. Urinary incontinence 
should be identified and dealt with in order to improve the quality of life for COPD patients.  
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Urinary Incontinence and Chronic Obstructive Pulmonary Disease 
Urinary incontinence has important social and psychological impacts that affect the lifestyles 
of older adults. However, it is not often recognised by physical therapists as a health problem 
in Japan despite the substantial reduction in quality of life of the individual concerned. This 
paper reviews the prevalence of urinary incontinence and chronic obstructive pulmonary 
disease (COPD) and investigates the relationship between them. The issues will be discussed 
from the perspective of the health burden that urinary incontinence imposes now and in the 
future on Japanese women, with implications for the physical therapist profession. A review 
of the literature was conducted by searching PubMed, Cochrane, CINAHL, ProQuest and 
other electronic databases, with keywords such as “urinary incontinence”, “chronic 
obstructive pulmonary disease”, and “adult women”, without any limitation on the year of 
publication. 
 
Chronic Obstructive Pulmonary Disease 
COPD is defined to be “a disease state characterized by airflow limitation that is not fully 
reversible. The airflow limitation is usually both progressive and associated with an 
abnormal inflammatory response of the lungs to noxious particles or gases”.1 The 
characteristic symptoms of COPD are cough, sputum production, and dysponea upon 
exertion. Chronic cough and sputum production typically precede the progress of airflow 
limitation by many years.1-3 Additionally, COPD is associated with systematic inflammation 
and skeletal muscle dysfunction. As the disease progresses, exercise tolerance becomes 




COPD is classified into four stages of severity based on airflow limitation as measured by 
spirometry,1 details of the classification are given in Table 1. It has been established that 
COPD results from the interaction of host factors and environmental exposures.1-4 Host 
factors include genetic predisposition, airway hyper-responsiveness and lung growth, while 
environmental exposures refer to polluted air, inhaled particles and gases. Worldwide, 
tobacco smoking is considered to be the most important aetiological factor.1-4 Exposures to 
inhaled particles and gases cause chronic inflammation of the mucosa of the airways leading 
ultimately to COPD. Even after exposures have ceased, it may be many years before their 
pathological effect stabilizes, during which the disease may continue to progress. Meanwhile, 
lung function continues to deteriorate as part of the normal aging process. 
[Table 1 here] 
 
Prevalence 
Accurate epidemiological data on COPD are difficult to collect. The prevalence and the 
morbidity of COPD are usually under-estimated because COPD is often under-diagnosed until 
it is clinically apparent.4 Moreover, there are alternative definitions of COPD in use, making it 
hard to estimate the true prevalence of the disease.1 
 
Epidemiological studies have indicated that the prevalence, morbidity and mortality of COPD 
have increased over recent years in Asia and the USA.5,6  In Europe, the prevalence of COPD 
is projected to increase over the next 20 years before reaching a plateau, whereas the Japanese 
prevalence will continue to increase over the next 40 years.7 The Nippon Epidemiology Study 
(NICE Study) reported a COPD prevalence of 10.9% (5% for females and 16.4% for males) 
for the Japanese population aged > 40 years in 2000.8 The prevalence was significantly higher 
among subjects aged 60’s (15.7%) and older (24.4%) than those at 40-49 years (3.5%) and 
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50-59 years (5.8%). However, the NICE Study did not illustrate the prevalence of COPD by 
gender and age groups. Only one hospital-based study showed the prevalence of COPD by 
gender and age groups.9 The survey recruited 12,760 subjects (8,659 males and 4,101 
females) aged 30 years or over, who were in a hospital to undergo a complete medical 
checkup between June 1997 and December 2001. The results, given in Table 1 (Physical 
characteristics and prevalence of COPD by gender and age groups) of Takemura et al,9 
showed that the prevalence of COPD had increased considerably amongst females aged over 
60 years (5.8%) and amongst males over 50 years (6.9%) and over 60 years (11.5%). Because 
only a few elderly subjects were recruited, these estimates tend to be more conservative than 
those of the NICE Study. Nevertheless, it may be concluded from both studies that the 
prevalence of COPD had increased with the aging population. 
 
In Japan, tobacco consumption is high and still rising for young women.7,10 The prevalence of 
Japanese male smokers aged 20 years and over has decreased from 83.7% in 1966 to 46.9% in 
2004.10 On the other hand, the proportion of female smokers has remained steady at around 
14% since 1960.11,12 The Japanese Ministry of Health, Labour and Welfare documented that 
the proportion of young female smokers aged 20-29 years has actually increased from 6.6% in 
1965 to 24.3% in 2002.10 This increase in female smoking rates will lead to a rising COPD 
prevalence for Japanese women in the future. Unlike Japan (14%), the prevalence of female 
smoking appears to be much lower in other Asian countries: 4.2% for Chinese women aged 
15 years and over in 1996,13 5.4% for Korean women aged 30 years and over in 2001,14 3.1% 
for Singaporean women aged 18 years and over in 1998,15 and 3.4% for Vietnamese women 
aged 15 years and over in 1997.15   
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Table 2 shows the expected prevalence of COPD by age groups for Japanese women in 2000 
and 2025, based on information from the U.S. Census Bureau16 and the hospital-based 
survey.9 The estimates are obtained from multiplying the projected population size of 
Japanese women by the prevalence of COPD for each age group. The prevalence of COPD 
for females below 60 years is expected to decrease gradually due to population decline, 
whereas the prevalence for those above 70 years will increase from 518 thousand in 2000 to 
911 thousand in 2025. The dramatic increase in the older group may be attributed to the aging 
population and the current increasing trend in cigarette consumption by female adolescents.  
[Table 2 here] 
    
Mortality and cost 
COPD has significant economic effects on the Japanese healthcare system. The total number 
of deaths from COPD increased linearly from 4000 in 1970 to over 13,600 in 2003 in 
Japan.17,18 The average length of hospital stay per admission was 37.8 days, which was longer 
than other respiratory diseases such as pneumonia (31.5 days) and asthma (13.3 days).17 In 
particular, the duration of hospitalisation for female COPD patients over 65 years was much 
longer (60 days), incurring large expenditure for their inpatient stay. The total average cost 
per patient with moderate to severe COPD has been estimated to be ￥435,876 annually.19 
The total annual cost for female COPD patients will increase 1.2 fold from ￥614 billion in 
2000 to ￥753 billion in 2025. Currently, those above 70 years accounted for about 30% of 
the total costs, but will exceed 50% of the total costs for women by 2025. 
  
Urinary incontinence and COPD 
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As COPD progresses, one of the clinical conditions, urinary incontinence, becomes more 
common. The International Continence Society (ICS) defined urinary incontinence as “a 
condition where involuntary loss of urine is a social or hygienic problem and is objectively 
demonstrable”. However, this definition is difficult to apply in practice.20-22 Hampel et al. 
consequently classified incontinence into three categories: 
I. Any uncontrolled urine loss in the prior 12 months without regard to severity; 
II. Includes information regarding the number of incontinence episodes, more than two in a 
month; 
III. The ICS definition; 
and demonstrated that the incidence rate based on the broad definition I was higher than that 
based on the ICS definition.23 It is thus difficult to compare prevalence rates of urinary 
incontinence across countries because of the different definitions in use. 
 
Aetiology 
The impacts of urinary incontinence for patients with COPD have been under-reported.24 
Urinary incontinence may not be considered as important as other symptoms such as airflow 
limitation. Furthermore, patients may be less aware of intermittent episodes of urinary 
incontinence and small amounts of urine leakage.24-26 This lack of perception and knowledge 
about urinary incontinence by COPD patients often leads to delay in seeking assistance and 
treatment from physical therapists.   
 
COPD is one of the factors associated with urinary incontinence. A European study of 1,531 
women (mean age 76.9±7.6 years) reported that the odds ratio of urinary incontinence for 
COPD was 1.53 (95% CI 1.11 to 2.12),27 while the odds ratio was 1.4 (95% CI 1.1 to 1.9) 
from a USA study of 7,949 women (mean age 76.9±5.0 years).28 Although another study of 
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2,767 Italian women aged over 40 years did not attain statistical significance,29 evidence has 
suggested a causal relationship between urinary incontinence and COPD.   
 
The higher risk of incontinence among women with COPD may be due to increasing 
abdominal pressure when coughing and, consequently, stress incontinence occurs.27 
Contraction of abdominal muscles during coughing can lead to a sudden rise in intra-
abdominal pressure, which then pushes up the diaphragm and increases the intra-pleural 
pressure, producing high expiratory flow rates. The pelvic floor muscles have to contract 
forcefully. When the process fails to occur, or is insufficient to overcome the increased 
pressure generated by coughing, urinary incontinence will occur. Patients with COPD are 
therefore at a higher risk of developing urinary incontinence.25,30,31 A cross-sectional study of 
42 men and 29 women have suggested breathlessness could contribute to an increasing risk of 
urinary incontinence although the evidence is still inconclusive.24  
 
Prevalence  
There is no published report on the prevalence of urinary incontinence for Japanese women 
with COPD. In the literature, the prevalence of urinary incontinence among female patients 
with chronic lung disease (cystic fibrosis) varied between 30.4% and 68%.25-30,32,33 This 
prevalence was comparatively higher than those of the general population (25-56.9%)34-36 and 
outpatient clients attending gynecology clinics (27-31%).37-39 Table 3 shows the age-specific 
prevalence of urinary incontinence for Japanese women seen in obstetrics and gynecology 
clinics from two separate studies.37,38 Assuming the age specific rates of urinary incontinence 
remain constant as the Japanese population ages, the number of female COPD patients with 
urinary incontinence would increase. The numbers of women with urinary incontinence are 
estimated and presented in Table 4, using population data from the U.S. Census Bureau16 and 
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a recent Northern Ireland survey of urinary incontinence among women with chronic lung 
disease.32 The 2000 and 2025 estimates are obtained from multiplying the projected 
population size of Japanese women by the prevalence of urinary incontinence for women with 
chronic lung disease (30.4%), which should be considered as conservative when compared to 
prevalence estimates from other studies.25-30, 33 By 2025 there will be an additional 134 
thousand women over 70 years with urinary incontinence due to COPD.  
[Table 3 and Table 4 here] 
 
Cost and burden  
Urinary incontinence incurs direct, indirect, and intangible costs. Direct cost includes routine 
care, treatment, and acute and chronic complications. Routine care incurs costs of various 
items such as pads, disposal and reusable underpants, laundry, skin care, and odour control 
products. Pads account for 70% of personal cost.21 With respect to indirect costs, urinary 
incontinence often has adverse effects on sleeping, leading to fatigue at work and loss of 
concentration, as well as interference with job performance. These limitations in daily living 
may result in altered social interaction, lost of self-esteem, and even depression.21 Intangible 
costs represent the monetary value of the resulting pain and suffering, the more severe the 
status of incontinence the higher the personal costs.  
 
There have been no published reports on the economic burden associated with urinary 
incontinence in Japan. In the USA, the societal cost per individual attributed to urinary 
incontinence was US$2,052 (￥209,000) in 1984, but increased by 174% to US$3,565 
(￥364,000) in 1995.40 Based on these costing data, it is estimated that urinary incontinence 
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for Japanese women with COPD incurred ￥119 billion in 2000 and the cost would be 
inflated to ￥165 billion by 2025.  
 
Conclusion 
The prevalence of COPD is rising with the aging population and the high tobacco 
consumption, especially for Japanese women. The number of female COPD patients above 70 
years of age is estimated to be 920 thousand by 2050. The symptoms of COPD often lead to 
urinary incontinence. Consequently, the prevalence of urinary incontinence also trends to 
increase. It is estimated that 134 thousand more women aged over 70 years will sustain 
urinary incontinence by 2025. The associated expenditure will be a substantial burden on the 
healthcare system. Urgent attention is thus required and additional resources should be 
allocated to combat this disease. Since COPD is preventable and urinary incontinence is a 
curable condition, a coordinated strategy in tobacco control by the government in conjunction 
with physical therapists is essential. An effective screening program is also needed for the 
early diagnosis of COPD to improve quality of life of the patients. In addition, regular 
assessment for urinary incontinence and appropriate rehabilitation coupled with exercise 
programs should be advocated by physical therapists. Therefore, the involvement of the 
physical therapy profession is particularly important and would play a significant role in 
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Table 1. Classification of COPD by severity1 
 
Stage Characteristics 
0: At Risk Normal spirometry 
 Chronic symptoms (cough, sputum production) 
I: Mild COPD FEV1/FVC < 70% 
 FEV1 ≥ 80% predicted 
 With or without chronic symptoms (cough, sputum production) 
II: Moderate COPD FEV1/FVC < 70% 
 50% ≤ FEV1 < 80% predicted 
 With or without chronic symptoms (cough, sputum production, dyspnoea)
III: Severe COPD  FEV1/FVC < 70% 
 30% ≤ FEV1 < 50% 
IV: Very Severe COPD FEV1/FVC < 70% 
 FEV1 ≤ 30% predicted or FEV1< 50% predicted plus respiratory failure 
 
 
FEV1 = forced expiratory volume in the first second 
FVC = forced vital capacity  
16 
Table 2. Estimated number (thousands) of Japanese women with COPD by age groups in 
2000 and 2025 
  
Year 30-39 40-49 50-59 60-69 ≥70 
2000 124.2 100.4 221.3 445 517.6 




Table 3. Prevalence (%) of urinary incontinence by age groups for Japanese women in 
obstetrics and gynecology clinics from two studies37,38 
 
Year 20-29 30-39 40-49 50-59 60-69 ≥70 Overall 
1998 12.4 30.4 36 44.1 40 44.5 31 




Table 4. Estimated number (thousands) of urinary incontinent Japanese women with COPD 
by age groups in 2000 and 2025 
 
Year 30-39 40-49 50-59 60-69 ≥70 
2000 42.2 34.1 75.3 151.3 176 
2025 31.3 31.7 70.1 144.9 309.6 
 
 
